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A B S T R A C T
Mycobacterium chelonae is a rapidly growing mycobacterium that has the potential to cause refractory infections
in humans. Mycobacteremia resulting from the organism is extremely rare, and its clinical features are yet to
be uncovered. We herein present a case of M. chelonae bloodstream infection involving an immunocompromised
older patient. A 79-year-old woman, on a long-term treatment with prednisolone plus tacrolimus for rheuma-
toid arthritis, visited our outpatient department complaining of deteriorating pain and swelling at her right 1st
toe. Laboratory parameters showed elevated C-reactive protein and leukocytosis, and magnetic resonance imag-
ing indicated osteomyelitis at the proximal phalanx of her right 1st toe. Considering the refractory course, the
infected toe was immediately amputated. M. chelonae was isolated from bacterial cultures of the resected tissue
and blood (BD BACTEC™ FX blood culture system, Becton Dickinson, Sparks, MD, USA), leading to a diagnosis
of disseminated M. chelonae infection. We treated the patient with an antibiotic combination of clarithromycin,
minocycline, and imipenem (2 weeks), which was converted to oral therapy of clarithromycin, doxycycline, and




Non-tuberculous mycobacteria (NTM) are ubiquitously distributed
across a range of environments, such as soil, natural waters, and tap wa-
ter [1]. The organisms are generally non-pathogenic to humans; how-
ever, they occasionally cause a wide variety of infectious diseases, par-
ticularly in those with impaired cell-mediated immunity [2,3]. NTM
bloodstream infection is a severe form of extrapulmonary NTM disease.
Reports on the hematogenously-disseminated NTM diseases have been
mainly described in patients with human immunodeficiency virus in-
fection [4,5]. However, literature has suggested that various immuno-
compromised conditions such as organ transplantation, chronic corticos-
teroid therapy, oncogenic diseases, and congenital or acquired anti-IFNγ
autoantibody can also expose patients to a risk of NTM bloodstream in-
fection [6].
In this report, we illustrate a rare case of Mycobacterium chelonae
bloodstream infection, induced by osteomyelitis at the right 1st toe of a
rheumatic patient undergoing immunosuppressive therapy.
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2. Case report
A 79-year-old woman presented to our hospital with a complaint of
a deteriorating pain and swelling on her right 1st toe. The patient had
a history of rheumatoid arthritis, interstitial lung disease, steroid dia-
betes, and diabetic nephropathy (stage G3b). The patient had been on a
long-term treatment of 7.5 mg per day of prednisolone (3 years) and 2
mg per day of tacrolimus (2 years). She did not have symptoms of night
sweat but was exhibiting weight loss. Her general status was distressed;
her activities of daily living were impaired due to disuse muscle atro-
phy and malnutrition. She had suffered from the painful and swollen
toe one month prior to admission, which was treated with oral antibi-
otics (250 mg of amoxicillin-clavulanate twice daily) under a diagnosis
of cellulitis. However, the inflammatory manifestations did not improve
(Fig. 1A), and magnetic resonance imaging (MRI) scan was indicative
of osteomyelitis at the proximal phalanx of the right 1st toe (Fig. 1B).
The patient was subsequently admitted to our hospital for further treat-
ment.
Initial vital signs on admission were as follows: heart rate, 90 beats
per minute; blood pressure, 138/81 mmHg; peripheral oxygen satura-
tion, 99% on room air; and body temperature, 36.3 °C. She had an
extremely low body mass index of 12.7 (Kg/m2). There were no par-
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Fig. 1. Clinical and radiographic findings of osteomyelitis at right 1st toe. A, gross appear-
ance; Arrow indicates an inflammatory manifestation. B, T2 weighted image of magnetic
resonance imaging; Arrowhead indicates a signal change suggesting osteomyelitis.
lor and her inflammatory right toe. The patient did not show any spe-
cific symptoms such as chills and rigor, or high fever, which could sug-
gest a bloodstream infection. Laboratory data showed total leukocyte
count of 7010/mm3 (elevated neutrophil count of 6500/mm3 and de-
creased lymphocyte count of 300/mm3), decreased hemoglobin (9.7 g/
dL), elevated serum C-reactive protein (3.42 mg/dL) and procalcitonin
(0.15 ng/mL), a decreased renal function (cystatin C 1.49 mg/L, cys-
GFR 38.9 mL/min/1.73m2), hypoalbuminemia (serum albumin, 2.7 g/
dL), and low hemoglobin A1c (5.8%). On admission day, we initiated
intravenous antimicrobials of meropenem (1 g q12h) and vancomycin
(1.5 g q24h, and 1.0 g q24h from the second day considering her body
weight of 26.5 kg). Shortly after the hospitalization, the patient was
sent for a surgery to debride the infected toe. During the debridement,
however, we found a necrotic change of the tissue and finally per-
formed an amputation of the right 1st toe. Gram staining (Favor G “Nis-
sui”; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) of the resected tis-
sue detected Gram-positive microbes implying Mycobacterium species
(Fig. 2A). We additionally performed Ziehl-Neelsen staining and found
numerous acid-fast bacilli (Fig. 2B). A PCR test for Mycobacterium tuber-
culosis was negative. Two sets of blood culture samples drawn from dif-
ferent peripheral veins on hospitalization became positive after 5 days of
incubation period (BD BACTEC™ FX blood culture system, Becton Dick-
inson, Sparks, MD, USA). Gram staining and Ziehl-Neelsen staining of
the blood culture smears also revealed acid-fast bacilli (Fig. 2C and D).
Under a diagnosis of disseminated mycobacterium infection, specif-
ically caused by a rapidly growing mycobacterium, we administered a
combination of oral clarithromycin (400 mg q12h), oral minocycline
(100 mg q12h), and intravenous imipenem-cilastatin (0.5 g q8h). The
organism detected from both the resected tissue and blood were identi-
fied to be M. chelonae using mass spectrometry (MALDI Biotyper, Bruker
Daltonics Inc., Billerica, MA, USA). Also, the organism was identified
as M. chelonae by rpoB sequence analysis using following primer sets;
Forward 5′-CGA CCA CTT CGG CAA CCG-3′ and Reverse 5′-TCG ATC
GGG CAC ATC CGG-3′; 99.7% (297/298 bases) similarity to M. che-
lonae subsp. gwanakae strain MOTT36W chromosome [7]. Antimicro-
bial susceptibility testing showed the organism to be susceptible to
clarithromycin (minimal inhibitory concentrations (MICs): 0.25 μg/mL),
minocycline, imipenem-cilastatin, levofloxacin (MICs = 2 μg/mL), gen-
tamycin, and linezolid, depending on Frozen broth microdilution panels
(Eiken Chemical Co., Ltd., Tokyo, Japan).
A result of gallium scintigraphy was negative for any secondary in-
fected lesions. After two weeks of the combination therapy, the pa-
tient showed gradual improvements; she became afebrile and her phys-
ical activity ameliorated. In parallel, laboratory testing revealed nor-
malized level of serum C-reactive protein. The patient was transferred
to another hospital with oral antimicrobials of clarithromycin, doxycy
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cline (100 mg q12h), and levofloxacin (500 mg q 24 h). The patient has
remained on the triple therapy for 6 months with a good clinical course.
3. Discussion
We described a rare case of NTM bloodstream infection that oc-
curred in an immunocompromised patient. The patient had steroid-re-
lated diabetes mellitus as underlying condition, which was well con-
trolled on admission, and long-term use of prednisolone and tacrolimus
could be mainly responsible for the occurrence of disseminated dis-
ease. M. chelonae was detected from both the infected toe and the blood
specimen, leading to a final diagnosis of disseminated NTM infection.
Among various NTM species, M. chelonae has been infrequently reported
as a bacteremic pathogen of NTM [6,8]. Due to the slow-growing and
poor-staining nature of the pathogen, microbiological diagnosis of the
disease is challenging. In addition, due to the infrequency of the disease,
clinical features of M. chelonae bloodstream infection are yet to be eluci-
dated. Nevertheless, we successfully diagnosed the case and treated the
patient with surgical amputation and antibiotic combination therapy.
Clinical characteristics of NTM bloodstream infection are well sum-
marized in a case series with literature review published in 2016 [6],
followed by additional case reports [8–10]. According to this research,
the majority of cases involved those with immunocompromised condi-
tions, and our patient was presumably vulnerable to the rare infection
due to long-term use of immunosuppressive agents. The severe disease
shows a wide variety of clinical manifestations involving multiple or-
gans, such as the lungs, endocardium, brain, spinal cord, and soft tis-
sues. Additionally, osteomyelitis is reportedly a possible infectious focus
of the NTM bloodstream infection as well [11,12]. According to the pre-
ceding literature, the median time to positive blood culture results was
11.5 days (interquartile range of 6.8–18.8 days), including non-rapidly
growing mycobacteria [6]. Rapidly growing mycobacteria can be de-
tected from blood culture in a shorter incubation period, such as 5 or
6 days [8,10], as demonstrated in our case. However, reliable data on
blood culture positivity and prognosis of NTM bloodstream infection re-
mains unclear due to the rarity of the disease.
Early recognition of NTM infection leads to a good outcome with
less recurrence [13]. Because NTM is barely unstained by Gram-staining
[11], diagnosis of the disease is generally challenging. In our case; how-
ever, the organism was initially suspected via Gram-staining, leading to
a successful identification of the pathogen by additional Ziehl-Neelsen
staining.
The treatment strategy for NTM bloodstream infection includes a
combination of antibiotic therapy and surgical debridement. Focusing
on M. chelonae, the organism is reportedly susceptible to macrolides
(clarithromycin and azithromycin), aminoglycosides (tobramycin and
amikacin), tetracyclines (minocycline and doxycycline), and imipenem
[14]. Of these, macrolides are considered a key drug for NTM infec-
tion, and a combination of these antimicrobials in the initial phase of
the disease can yield a better outcome [15,16]. Antimicrobial suscepti-
bility testing in this case (frozen broth microdilution panel) is not rec-
ommended by Clinical & Laboratory Standards Institute (CLSI) guide-
line (M24-A2) [17], and thus, our results may be unreliable. Sensitiser
kit (Thermo Fisher Scientific, Waltham, MA, USA) is reportedly well
equivalent with the CLSI standard, which is, however, commercially un-
available in Japan [18]. No guidelines or gold standards for the opti-
mal duration of anti-mycobacterial chemotherapy have yet been devel-
oped. However, at least 4–6 weeks of multiple antibiotic therapy af-
ter improvement of clinical signs is suggested for NTM osteomyelitis
[11], and 12–36 months of the anti-NTM drugs successfully treated pa-
tients with NTM bloodstream infection [6]. We administered antibi-
otic combination therapy on the basis of clarithromycin without using
aminoglycosides because of her renal dysfunction. In addition to an-
tibiotic therapy, surgical debridement is often essential to treat such
cases [11]. According to a recent report on NTM musculoskeletal infec-
tions, all the fourteen patients required surgical interventions in combi-
nation with antibiotics to control the diseases [12]. Thus, we believe the
early amputation of the infected toe combined with long-term antibiotic
treatment in this case could have contributed to the good outcome of the
patient.
In summary, we illustrated a clinical course of M. chelonae blood-
stream infection. A growing number of immunocompromised patients
are exposed to a risk of severe NTM disease, especially the current age-
ing society. This case highlighted that physicians should consider the
possibility of this rare but refractory infection, especially in older people
who are under immunocompromised conditions.
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